Thursday, August 25, 2016

Leerink reiterates rating on Aurinia following trial results

Leerink reiterates rating on Aurinia following trial results

August 15, 2016 by · Leave a Comment 

Tweet Leerink reiterated its “outperform” rating on Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP) after the reported top-line results with voclosporin in a Phase 2b clinical study in patients with active lupus nephritis. Analyst Joseph Schwartz writes that the study met its primary endpoint of complete remission and improvements in partial remission versus placebo. While efficacy was higher […]

XTL hopes to begin major lupus trial next year

XTL hopes to begin major lupus trial next year

July 22, 2014 by · Leave a Comment 

Tweet XTL Biopharmaceuticals (NASDAQ:XTLB; TASE:XTL) is aiming to begin a Phase 2b clinical trial in the first half of 2015 with its hCDR1 peptide to treat patients with systemic lupus erythematosus (SLE). “We are in the process of finalizing our trial design, approaching the FDA and hope to have feedback from the agency before the […]

Ciclofilin developing first drug for HCV/HIV-1 co-infection

Ciclofilin developing first drug for HCV/HIV-1 co-infection

June 24, 2014 by · Leave a Comment 

Tweet Closely held Ciclofilin Pharmaceuticals is developing what, it hopes, will be the first clinically effective treatment for hepatitis C virus (HCV)/HIV-1 co-infection, with specific antiviral activity directed against both viruses. “Other companies are working on one or the other virus, so we would like to position ourselves as the company working on co-infection, where […]

Aurinia to begin lupus nephritis trial at end of April

Aurinia to begin lupus nephritis trial at end of April

April 15, 2014 by · Leave a Comment 

Tweet Fresh from a US$52-million private placement, Aurinia Pharmaceuticals (TSX-V:AUP) hopes to treat its first lupus patient at the end of April in a Phase 2b clinical trial with its voclosporin immunosuppressant in combination with CellCept®, the standard of care for treating lupus nephritis (LN), the most severe form of lupus. “We are now well capitalized […]

Aurinia readies Phase 2b trial in lupus nephritis

Aurinia readies Phase 2b trial in lupus nephritis

November 19, 2013 by · Leave a Comment 

Tweet Aurinia Pharmaceuticals (TSX-V:AUP) is preparing to begin a Phase 2b clinical trial in the first quarter of 2014 with its voclosporin immunosuppressant in combination with CellCept, the standard of care for treating lupus nephritis (LN), the most severe form of lupus. “The core of our management team executed the Aspreva Lupus Management Study, which […]

Aurinia makes post-merger management changes

Aurinia makes post-merger management changes

October 22, 2013 by · Leave a Comment 

Tweet Aurinia Pharmaceuticals (TSX-V:ISA), formerly Isotechnika Pharma, unveiled a post-merger strategic restructuring, including senior management changes, designed to further position the company to successfully bring voclosporin to market as a therapy for lupus nephritis. Dr. Richard Glickman has been appointed executive chairman and acting CEO, succeeding Dr. Robert Foster, who moves to the post of […]

Isotechnika, Aurinia complete merger, financing

Isotechnika, Aurinia complete merger, financing

September 23, 2013 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX:ISA) and Aurinia Pharmaceuticals have completed their merger and will operate under the name, Aurinia Pharmaceuticals. The transaction was approved by shareholders on Aug. 15. In connection with the merger, the company has completed, subject to regulatory approval, a private placement of 133,333,332 units, consisting of one common share and one half […]

Isotechnika gets more funding for NICAM program

Isotechnika gets more funding for NICAM program

June 18, 2013 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX: ISA) has received additional funding from the National Research Council Industrial Research Assistance Program (NRC-IRAP) for its non-immunosuppressive cyclophilin antagonist molecules (NICAM) program. NRC-IRAP continues to play an instrumental role in networking the NICAM program with key global partners and previously assisted Isotechnika in late-stage screening of several NICAM compounds, including […]

Takeda deal in lupus highlights Isotechnika-Aurinia merger potential

Takeda deal in lupus highlights Isotechnika-Aurinia merger potential

February 28, 2013 by · Leave a Comment 

Tweet A $255-million development partnership between Takeda Pharmaceutical and Resolve Therapeutics to develop compounds for the treatment of lupus and other autoimmune diseases highlights the potential of a merger between Isotechnika Pharma (TSX:ISA) and Aurinia Pharmaceuticals to develop Isotechnika’s voclosporin drug for lupus nephritis. Resolve’s lead compound, RSLV-132, will begin clinical development later this year. […]

Isotechnika merger with Aurinia to create nephrology leader

Isotechnika merger with Aurinia to create nephrology leader

February 5, 2013 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX:ISA) and closely-held Aurinia Pharmaceuticals have signed a binding term sheet to merge and create a premier clinical-stage pharmaceutical company focused on the global nephrology market. Aurinia is a spin-out from Vifor Pharma, the pharmaceutical arm of Swiss-based Galenica Group. Aurinia’s current leadership team is comprised primarily of former senior managers, directors […]

Next Page »

Email Newsletters with Constant Contact
Google+